A Phase II Study With a Safety lead-in of Nivolumab in Combination With Bevacizumab or in Combination With Bevacizumab and Rucaparib for the Treatment of Relapsed Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 30 Aug 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Nivolumab (Primary) ; Rucaparib (Primary)
Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

28 Aug 2024 Planned End Date changed from 1 Jul 2026 to 1 Oct 2026.
28 Aug 2024 Planned primary completion date changed from 1 Jul 2024 to 1 Oct 2024.
06 May 2024 Planned End Date changed from 1 Mar 2025 to 1 Jul 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight